Macrocyclic indoles as hepatitis C virus inhibitors

Patent metadata

Field	Value
Publication number	US-9334282-B2
Application number	US-201313908705-A
Country	US
Kind code	B2
Filing date	Jun 3, 2013
Priority date	Dec 24, 2007
Publication date	May 10, 2016
Grant date	May 10, 2016

Abstract

The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof,

wherein R 1 ; R 3 ; and R 4 have the meaning defined in the claims.

The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

First claim

The invention claimed is:

1. A compound having the formula (I) or an N-oxide, stereoisomer, tautomer, racemic or salt thereof, wherein

R 1 is a bivalent chain selected from

wherein the sulfonyl group is attached to the remainder of the molecule via the nitrogen atom of the amide group, and the carbon atom of the acetamide moiety is attached to the remainder of the molecule via the nitrogen of the indole ring of the compound of formula (I);
X is selected from —CR 5a R 5b — or —NR 5a —;
each of g and h is, independently, an integer selected from 0, 1, 2, 3, 4, or 5, with the proviso that the macrocycle formed by the bivalent chain R 1 , the —C(═O)—NH— moiety to which R 1 is attached and the nitrogen and carbon atoms N1, C6, C7, and C7′ of the indole ring, has from 14 to 17 member atoms;
each parallel dashed line (represented by ) represents an optional double bond;
R 2 is hydrogen or C 1-6 alkyl;
R 3 is C 3-7 cycloalkyl;
R 4 is a group selected from:

R 5a and R 5b are each independently selected from hydrogen; C 1-6 alkyl; or haloC 1-6 alkyl;
n is 0, 1, or 2;
R 6 is selected from hydrogen, halo, C 1-6 alkyl, or C 3-7 cycloalkyl;
R 6a is selected from hydrogen, halo, C 1-6 alkyl, or C 3-7 cycloalkyl;
R 7 is phenyl or thiazolyl, wherein each phenyl is optionally substituted with one, two, or three substituents, wherein each thiazolyl is optionally substituted with one or two substituents; wherein the substituents on both phenyl and thiazolyl are each independently selected from halo; cyano; nitro; C 1-6 alkyl; —OR 12 ; —C(═O)OR 12 ; —C(═O)R 13 ; —C(═O)NR 9a R 9b ; —NR 9a R 9b ; —NR 9a C(═O)R 13 ; —NR 9a C(═O)—CH 2 —NR 9a R 9b ; —SR 10 ; —SO 2 R 11 ; —SO 2 NR 9a R 9b ; phenyl optionally substituted with one, two or three substituents each independently selected from halo, trifluoromethyl, cyano, C 1-6 alkyl, C 1-6 alkoxy, and —C(═O)NR 9a R 9b ; and Het optionally substituted with one or two substituents each independently selected from oxo, C 1-6 alkylsulfonyl, and C 1-6 alkyl;
R 8 is hydrogen, phenyl, or thiazolyl, wherein each phenyl is optionally substituted with one, two, or three substituents, wherein each thiazolyl is optionally substituted with one or two substituents; wherein the substituents on both phenyl and thiazolyl are each independently selected from halo; cyano; nitro; C 1-6 alkyl; —OR 12 ; —C(═O)OR 12 ; —C(═O)R 13 ; —C(═O)NR 9a R 9b ; —NR 9a R 9b ; —NR 9a C(═O)R 13 ; —NR 9a C(═O)—CH 2 —NR 9a R 9b ; —SR 10 ; —SO 2 R 11 ; —SO 2 NR 9a R 9b ; phenyl optionally substituted with one, two or three substituents each independently selected from halo, trifluoromethyl, cyano, C 1-6 alkyl, C 1-6 alkoxy, and —C(═O)NR 9a R 9b ; and Het optionally substituted with one or two substituents each independently selected from oxo, C 1-6 alkylsulfonyl, and C 1-6 alkyl;
R 9a and R 9b are each independently selected from hydrogen, C 1-6 alkyl, or arylC 1-6 alkyl; or R 9a and R 9b , together with the nitrogen to which they are attached, form a saturated, partially unsaturated, or completely unsaturated 5-8 membered monocycle, wherein said monocycle optionally contains one additional heteroatom selected from the group consisting of oxygen, sulfur and nitrogen, and wherein the remaining monocycle members are carbon atoms;
wherein said monocycle is optionally substituted on any carbon atom with one or two substituents each independently selected from halo, C 1-6 alkyl, hydroxy, or oxo, wherein aryl is phenyl or naphthyl;
R 10 is C 1-6 alkyl or C 3-7 cycloalkyl;
R 11 is C 1-6 alkyl or C 3-7 cycloalkyl;
R 12 is hydrogen, C 1-6 alkyl, or benzyl;
R 13 is C 1-6 alkyl;
Het is pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl.

2. A compound as claimed in claim 1 wherein
R 1 is

wherein the carbon atom carrying the R 5a and R 5b substituents (the left side of the depicted R 1 chains) is attached to the remainder of the molecule via the nitrogen atom of the amide group, and the carbon atom of the acetamide moiety (the right side of the depicted R 1 chains) is attached to the remainder of the molecule via the nitrogen of the indole ring of the compound of formula (I);
each parallel dashed line (represented by ) represents an optional double bond; and
R 4 is a group selected from:

3. A compound according to claim 1 , having the structural formula

wherein the parallel dashed line, g, h, R 3 , R 6 , R 7 , X, n, and R 8 , have the same meaning as that defined in claim 1 .

4. A compound according to claim 1 wherein R 4 is

5. A compound according to claim 1 , wherein R 4 is

6. A compound according to claim 1 , wherein R 1 is

7. A compound according to claim 1 , wherein each of g and h is, independently, 0, 1, 2, or 3, with the proviso that the macrocycle formed by the bivalent chain R 1 , the —C(═O)—NH— moiety to which R 1 is attached and the nitrogen and carbon atoms N1, C6, C7, and C7′ of the indole ring, has from 14 to 16 member atoms.

8. A compound according to claim 1 , wherein R 2 is hydrogen or C 1-4 alkyl.

9. A pharmaceutical composition comprising an anti-virally effective amount of a compound as claimed in claim 1 and a pharmaceutically acceptable carrier.

Assignees

• Janssen R&D Ireland
• Janssen Sciences Ireland Uc

Inventors

• Raboisson Pierre Jean-Marie Bernard
• Hu Lili
• Vendeville Sandrine Marie Helene
• Nyanguile Origéne
• Tahri Abdellah

Classifications

• A61P31/12

  Antivirals · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/18

  for HIV · CPC title

• C07D513/08

  Bridged systems · CPC title

• C07D513/06

  Peri-condensed systems · CPC title